#USA #New York #Cognition #Cognizin® #Kyowa Hakko

Kyowa Hakko USA's Breakthrough Research on Cognizin® Citicoline

Kyowa Hakko USA, a leader in health ingredient innovation, is etching its name in the annals of cognitive health research with the latest findings on its flagship product, Cognizin® Citicoline. Set to present at the International Society of Sports Nutrition (ISSN) Annual Conference, the new proof-of-concept study reveals significant acute cognitive enhancements achieved through a single dose of Cognizin®. This study not only underscores the efficacy of Citicoline as a cognitive health ingredient but also highlights its immediate benefits in brain function.

Understanding Cognizin® Citicoline

Cognizin® is a highly validated, clinically studied form of citicoline that has been utilized for its cognitive benefits for over three decades. Scientific literature supports its role in boosting focus, mental energy, attention, and memory. The new study ventures beyond the established long-term benefits of extended supplementation, assessing the impact of a 500 mg dose of Cognizin® in a controlled environment.

Study Design and Findings

The research employed a randomized, double-blind, placebo-controlled crossover design involving healthy male adults. Participants received either Cognizin® or a placebo, and their cognitive responses were assessed through a battery of neurophysiological measurements, including electroencephalogram (EEG) analysis and validated cognitive tasks. Evaluations at both 60 and 240 minutes post-dosing provided crucial insights into the onset and duration of the cognitive effects.

Dr. Katie Emerson, senior manager of scientific affairs at Kyowa Hakko USA, emphasized, "This study offers exciting revelations regarding Cognizin® and its rapid impact on brain function. We are thrilled to share our findings with the scientific community and the broader public at the 2026 ISSN Annual Conference."

Implications for Cognitive Health

The implications of these findings extend across various sectors, impacting cognitive health formulations, sports nutrition, and functional food and beverage applications. As the cognitive health supplement market continues expanding, the study reaffirms Kyowa Hakko's commitment to science-backed innovations, positioning Cognizin® as a competitive ingredient in a saturated market.

The upcoming presentation will dissect methodological details and neurophysiological outcomes, offering a comprehensive picture of Cognizin®’s effects. The session will be presented by experts, including Dr. Emerson and Dr. Tim N. Ziegenfuss, shedding light on the clinical relevance of their findings for formulators, brand owners, and health enthusiasts alike.

About Kyowa Hakko USA

Kyowa Hakko USA is not merely a brand but a pioneer with over 75 years of excellence in fermentation technology. As part of Kirin Holdings' Health Science group, they specialize in providing high-quality, science-backed ingredients. Their portfolio includes other prominent products like Setria® Glutathione and Pantesin® Pantethine, catering to nutraceutical, pharmaceutical, and wellness sectors. The company is committed to sustainability and improving quality of life through innovative health solutions.

Conclusion

As cognitive health becomes an increasing focus in the wellness industry, Kyowa Hakko USA's continuous investment in cutting-edge research positions it at the forefront of cognitive health science. The study on Cognizin® Citicoline not only marks a notable advancement in understanding acute cognitive effects but also reinforces the importance of clinical research in developing effective health solutions. The complete findings will await those attending the ISSN Annual Conference, promising a wealth of insights into future applications in cognitive health.